MYCOPHENOLATE MOFETIL
Clinical Indication
Autoimmune conditions
Comments
Please see shared care agreement for individual indications
Date of classification
June 2021
Orange
Shared Care Agreement. Higher risk medicines requiring significant regular monitoring which would be initiated by or at the recommendation of a specialist service which may include mental health services, secondary care, tertiary care, community providers, private providers and GPs with a specialist interest.